Company: PHR
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001412408-25-000010
Chunk: 53

Company: Phreesia, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 53
---
 segment profit for the Technology solutions segment is equal to the Company’s Net loss presented on the accompanying consolidated statements of operations.The following table presents the Company’s segment revenue, segment profit (loss), significant segment expenses, and other segment items, as well as a reconciliation from segment profit (loss) to consolidated net loss.Fiscal years ended January 31,202520242023Revenue$419,813 $356,299 $280,910 Labor costs (1)224,792238,533240,532Payment processing expense68,70762,98650,323

111

Third-party non-labor operating expenses89,55090,15982,528Stock-based compensation66,97571,61358,775Other segment items28,31629,89324,898Segment net loss$(58,527)$(136,885)$(176,146)Reconciliation of profit or lossAdjustments and reconciling items$— $— $— Consolidated net loss$(58,527)$(136,885)$(176,146)(1) Excludes stock-based compensation expense which is presented separately Other segment items include depreciation and amortization, interest income, net, provision for income taxes, loss on extinguishment of debt and other income (expense), net.The total segment assets for the Technology solutions segment are equal to the total assets presented on the accompanying consolidated balance sheets. The following table presents other quantitative segment disclosures for the fiscal years ended January 31, 2025, 2024 and 2023, respectively.Fiscal years ended January 31,202520242023Depreciation and amortization$27,886 $29,487 $25,304 Interest income, net$330 $2,211 $1,064 Loss on extinguishment of debt$— $(1,118)$— Gain on settlement (included in other income (expense), net)$2,345 $— $— Provision for income taxes$(2,716)$(1,543)$(483)Expenditures for long-lived assets$25,940 $96,474 $17,270 

17. Acquisitions

On June 30, 2023, the Company entered into an agreement to acquire 100% of the outstanding equity of MediFind for aggregate consideration payable of $8,871 (the "MediFind Acquisition"). A portion of the consideration was paid in cash at closing (subject to a customary working capital